Clinical Trial Update: A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma [Phase 3]

View source ↗

Summary

This clinical trial update indicates a Phase III study (SHR-A2102 vs investigator-selected therapy) for advanced urothelial carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• SHR-A2102

Snippet

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Conditions: Advanced Urothelial Carcinoma | Phase 3 | Status: RECRUITING